OTCMKTS:NSPX Inspyr Therapeutics (NSPX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Inspyr Therapeutics Stock (OTCMKTS:NSPX) Get Inspyr Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume29.64 million shsAverage Volume13.19 million shsMarket Capitalization$1.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Inspyr Therapeutics, Inc. is a biotechnology company focused on the development of therapies for cancer and other serious diseases. The company has operated as a clinical-stage organization and has concentrated on novel drug candidates rather than marketed pharmaceutical products. Its principal development program has centered on mipsagargin, also known as G-202, a targeted prodrug based on thapsigargin. The candidate was designed to become active in the tumor microenvironment through prostate-specific membrane antigen, with the goal of selectively affecting solid tumors while limiting exposure to healthy tissue. Development efforts have included potential applications in cancers such as glioblastoma, renal cell carcinoma and other solid tumors. The company was formerly known as GenSia, Inc. and adopted the Inspyr Therapeutics name in 2016. Publicly available information provides limited detail regarding its current commercial operations, geographic reach and leadership. Inspyr Therapeutics has not been identified as having an approved commercial product, and its business remains primarily associated with biotechnology research and therapeutic development.AI Generated. May Contain Errors. Read More Receive NSPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inspyr Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NSPX Stock News HeadlinesInspyr Supports Breast Cancer Survivors with 'More Than Just a Pink Ribbon' EventOctober 1, 2024 | msn.comTG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, PredictionsMarch 4, 2023 | benzinga.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars. | Behind the Markets (Ad)Inspyr Therapeutics Announces New Holding Company Structure and Reverse Stock SplitOctober 12, 2021 | ca.finance.yahoo.comSee More Headlines NSPX Stock Analysis - Frequently Asked Questions How were Inspyr Therapeutics' earnings last quarter? Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) announced its quarterly earnings results on Monday, August, 14th. The company reported ($26.25) earnings per share (EPS) for the quarter. When did Inspyr Therapeutics' stock split? Shares of Inspyr Therapeutics reverse split on the morning of Tuesday, October 12th 2021.The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Company Calendar Last Earnings8/14/2017Today11/03/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:NSPX CIK1421204 Webrebus-corp.com Phone(818) 597-7552FaxN/AEmployees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.30 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,354.49% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / BookN/AMiscellaneous Outstanding Shares543,152,000Free FloatN/AMarket Cap$1.47 million OptionableNot Optionable Beta-17.33 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:NSPX) was last updated on 10/11/2021 by MarketBeat.com Staff. From Our PartnersFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution ri...Weiss Ratings | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inspyr Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inspyr Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
